|
Stories from the dialysis comunity across the globe.
|
|
CMS announces initial group of practices participating in the ACO (Accountable Care Organization) model. |
 |
 |
|
CMS: Overview The Advance Payment Model is designed for physician-based and rural providers who have come together voluntarily to give coordinated high quality care to the Medicare patients they serve. Through the Advance Payment ACO Model, selected participants will receive upfront and monthly payments, which they can use to make important investments in their care coordination infrastructure. The following Advance Payment ACOs were announced for the performance period that began on April 1, 2012:
|
|
|
Patient weight gain after change of acid concentrate supplier with same nominal dialysate sodium level. |
|
|
|
IJAO: Conclusions: Changing dialysate acid concentrates, both labeled 1:44 dilution, led to the delivery of a higher dialysate sodium, resulting in weight gains, increased pre-dialysis blood pressure, but less symptomatic intradialytic hypotension. Following readjustment of volumetric dialysate mixing, excess weight gains and increased blood pressure resolved over 4 weeks, highlighting the importance of checking the delivered dialysate sodium following a change in dialysate acid concentrate.
|
|
New body shape index, based on height, BMI, and waist circumference, predicts mortality risk. |
|
|
|
PLOS online: Conclusions. Body shape, as measured by ABSI, appears to be a substantial risk factor for premature mortality in the general population derivable from basic clinical measurements. ABSI expresses the excess risk from high WC in a convenient form that is complementary to BMI and to other known risk factors.
|
|
|
JASN early release: Rituximab shows good results in membranous nephropathy. |
|
|
|
JASN: All 24 patients who had at least 4 years of follow-up achieved complete or partial remission. Rates of remission were similar between patients with or without previous immunosuppressive treatment. Four patients died and four progressed to ESRD. Measured GFR increased by a mean 13.2 (SD 19.6) ml/min per 1.73 m2 among those who achieved complete remission. Serum albumin significantly increased and albumin fractional clearance decreased among those achieving complete or partial remission. Proteinuria at baseline and the follow-up duration each independently predicted the decline of proteinuria. Furthermore, the magnitude of proteinuria reduction significantly correlated with slower GFR decline (P=0.0001). No treatment-related serious adverse events occurred. In summary, rituximab achieved disease remission and stabilized or improved renal function in a large cohort of high-risk patients with IMN.
|
|
JASN RCT finds no benefits of 3 phosphorus binding drugs on vascular calcification in predialysis CKD.. |
|
|
|
JASN: Active therapy did, however, significantly increase calcification of the coronary arteries and abdominal aorta (coronary: median increases of 18.1% versus 0.6%, P=0.05; abdominal aorta: median increases of 15.4% versus 3.4%, P=0.03). In conclusion, phosphate binders significantly lower serum and urinary phosphorus and attenuate progression of secondary hyperparathyroidism among patients with CKD who have normal or near-normal levels of serum phosphorus; however, they also promote the progression of vascular calcification. The safety and efficacy of phosphate binders in CKD remain uncertain.
|
|
|
|
|
<< Start < Prev 471 472 473 474 475 476 477 478 479 480 Next > End >>
|
|
Page 480 of 4210 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
